Frontiers in Endocrinology

Association between different sodium-glucose co-transporter 2 inhibitors and the risk of dementia: a network meta-analysis

By Zhongru Meng, Wu Hui, Yang Miao, Wang Qi, Mingzhu Sha

Figure 1. Flowchart of literature retrieval. — Figure 1. Flowchart of literature retrieval.Flowchart of literature retrieval.Meng et al.

Meta-analysis of observational studiesInterventions

Declared no competing interests

The paper

Zhongru Meng, Wu Hui, Yang Miao, Wang Qi, Mingzhu Sha

Yancheng First People's Hospital

Frontiers in Endocrinology, 4 Aug 2026

doi.org/10.3389/fendo.2026.1777151 PubMed 42614235

Diabetes & Vascular Disease Research4 Oct 2026
SGLT2 inhibitors link to lower dementia risk than GLP-1 drugs
Drug Design, Development and Therapy5 Oct 2026
GLP-1 agonists linked to lower dementia risk after COVID-19
Frontiers in Aging Neuroscience4 Oct 2026
COVID-19 tied to higher dementia risk in older adults with diabetes
Journal of Alzheimer's Disease Reports4 Oct 2026
Statins cut Alzheimer's risk but raise other dementia risks